3-mercapto-N,N-dimethyl-benzamide | 801315-71-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-mercapto-N,N-dimethyl-benzamide
• 英文别名: 3-Mercapto-N,N-dimethylbenzamide；N,N-dimethyl-3-sulfanylbenzamide
• CAS: 801315-71-9
• 化学式: C₉H₁₁NOS
• 分子量: 181.258
• InChiKey: RYOIXDSPWWGLIW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-mercapto-N,N-dimethyl-benzamide 、 ethyl [4-(2-iodobenzyl)-5-methyl-3-phenyl-1H-pyrazol-1-yl]acetate 在 铜 、 potassium hydroxide 作用下， 以 水 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  2-(1H-Pyrazol-1-yl)acetic acids as chemoattractant receptor-homologous molecule expressed on Th2 lymphocytes (CRTh2) antagonists

  摘要：

  In this manuscript, the synthesis and biological activity of a series of pyrazole acetic acid derivatives as CRTh2 antagonists is presented. Biological evaluation in vitro revealed that the pyrazole core showed in several cases a different structure activity relationship (SAR) to that of related indole acetic acid. A potent series of ortho-sulfonyl benzyl substituents was found, from which compounds 27 and 63 were advanced to in vivo profiling. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.10.072
• 作为产物：
  描述：

  3,3'-disulfanediylbis(N,N-dimethylbenzamide) 在 盐酸 、 三苯基膦 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 2.92h， 生成 3-mercapto-N,N-dimethyl-benzamide
  参考文献：
  名称：

  [EN] QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS
  [FR] DERIVES DE QUINOLEINE UTILISES EN TANT QU'INHIBITEURS DE LA PHOSPHODIESTERASE

  摘要：

  根据本发明提供了化合物的新结构，其化学式为（I）或其药用盐，其中R1、R2、R19、R20和R34如规范中所述，以及制备这些化合物的方法、含有它们的配方和它们在治疗炎症性疾病中的用途。

  公开号：

  WO2004103998A1

文献信息

• New CRTH2 Antagonists
  申请人：Almirall, S.A.

  公开号：EP2526945A1

  公开（公告）日：2012-11-28

  The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.

  本发明涉及一种式(I)的化合物，以及制备这种化合物的方法，以及它们在治疗通过CRTh2拮抗活性可改善的病理状况或疾病中的应用。
• Quinoline derivatives as phosphodiesterase inhibitors
  申请人：Barker David Michael

  公开号：US20060178416A1

  公开（公告）日：2006-08-10

  There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20, and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

  根据本发明提供了公式(I)的新化合物或其药学上可接受的盐，其中R1、R2、R19、R20和R34如规范所述，以及制备它们的过程、包含它们的制剂和它们在治疗炎症性疾病方面的用途。
• Quinoline Derivatives As Phosphodiesterase Inhibitors
  申请人：Baldwin Ian Robert

  公开号：US20090312325A1

  公开（公告）日：2009-12-17

  There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20, and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

  根据本发明提供了一种新的化合物式(I)或其药学上可接受的盐，其中R1、R2、R19、R20和R34如规范所述，以及制备它们的过程、含有它们的制剂以及它们在治疗炎症性疾病方面的用途。
• Quinoline derivatives as phosphodiesterase inhibitors
  申请人：GLAXO GROUP LIMITED

  公开号：EP1944305A1

  公开（公告）日：2008-07-16

  There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20 and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

  根据本发明提供了式 (I) 的新型化合物或其药学上可接受的盐类（其中 R1、R2、R19、R20 和 R34 如说明书所述）、制备它们的工艺、含有它们的制剂以及它们在治疗炎症性疾病中的用途。
• QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1633748B1

  公开（公告）日：2008-03-05